New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
14:05 EDTMRKMerck presents early findings from Phase 1b study for pembrolizumab
Merck announced the first presentation of early findings from a Phase 1b study evaluating pembrolizumab, MK-3475, Merck’s investigational anti-PD-1 antibody, as a single-agent, monotherapy, in patients with PD-L1 positive, advanced head and neck cancer. Early data showed a best overall response rate of 20% with 29% of patients having stable disease as measured by RECIST criteria . Similar overall response rates were observed in Human papillomavirus, HPV-positive and HPV-negative patients – HPV infection is a risk factor for some types of head and neck cancer. In the study, tumor shrinkage was demonstrated in 51% of evaluable patients who had measurable disease with one post baseline scan, per RECIST criteria. These early findings will be presented in an oral session by Dr. Tanguy Seiwert, associate director of the Head and Neck Cancer Program and assistant professor of medicine at The University of Chicago, at the 50th Annual Meeting of the American Society of Clinical Oncology. “Recurrent and metastatic head and neck cancer carries a very poor prognosis, and often is accompanied by poor quality of life and disfigurement. Additional treatment options are urgently needed,” said Dr. Seiwert. “These early response data with pembrolizumab as monotherapy provide an encouraging proof of concept and support further study of this novel investigational immunotherapy in this hard-to-treat cancer type.” “We continue to observe robust signals of anti-tumor activity in response to pembrolizumab monotherapy across multiple tumor types and lines of therapy, including these data in head and neck cancer,” said Dr. Roy Baynes, senior vice president, global clinical development, Merck Research Laboratories. “The breadth of data to be presented at ASCO underscores why Merck is advancing a broad development program for pembrolizumab across more than 30 tumor types, including late-stage studies in head and neck and other cancers.”
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
07:35 EDTMRKCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 20, 2014
08:06 EDTMRKMerck, Sanofi unit announce pediatric hexavalent vaccine BLA
Subscribe for More Information
07:34 EDTMRKAdvaxis names Mauro Chief Medical Officer
Advaxis (ADXS) announced that it has appointed David Mauro, as executive vice president, Chief Medical Officer Mauro most recently served as executive director, section head oncology clinical development at Merck (MRK). In connection with his appointment, Mauro received a one-time inducement award of 165K restricted shares, of which 55K are fully vested and as of the grant date. The remaining shares vest annually over a two-year period.
07:19 EDTMRKIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTMRKAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
October 17, 2014
07:58 EDTMRKDeutsche Bank specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Gilbert provides of preview of The Improved Reduction of Outcomes: Vytorin Efficacy Internal Study (IMPROVE-IT) on an Analyst/Industry conference call to be held on October 17 at 10 am.
October 15, 2014
12:42 EDTMRKNY AG announces $31M Medicaid settlement with Organon
Subscribe for More Information
09:57 EDTMRKLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 14, 2014
11:23 EDTMRKBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
07:37 EDTMRKAmerican Society of Anesthesiologists to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use